<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48734">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02089828</url>
  </required_header>
  <id_info>
    <org_study_id>B2014-021</org_study_id>
    <nct_id>NCT02089828</nct_id>
  </id_info>
  <brief_title>Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia</brief_title>
  <official_title>Randomized Control Trial on Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral
      blood mononuclear cells in treatment of critical limb ischemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>major-amputation-free survival rate</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement on transcutaneous partial oxygen pressure</measure>
    <time_frame>at 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>improvement on peak pain-free walking time</measure>
    <time_frame>at 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Thromboangiitis Obliterans</condition>
  <condition>Arteritis</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>autologous purified CD34+ cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>transplantation of autologous purified CD34+ cell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>autologous PB-MNC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>transplantation of autologous peripheral blood mononuclear cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous purified CD34+ cells</intervention_name>
    <arm_group_label>autologous purified CD34+ cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous peripheral blood mononuclear cells</intervention_name>
    <arm_group_label>autologous PB-MNC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rutherford scale of 4-5

          -  thromboangiitis obliterans,  peripheral arterial disease, or arteritis caused by
             other etiologies, such as collagen diseases

          -  surgical or endovascular procedures are considered  unlikely to have successful
             long-term revascularization, or have failed

          -  more than 4 weeks of critical limb ischemia

          -  if present, a non-healing ulcer after more than 4 weeks of optimal care by a wound
             care physician and a nurse

        Exclusion Criteria:

          -  within 3 months of an acute myocardial infarction

          -  any contraindication for the administration of granulocyte colony stimulating factor
             (G-CSF)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiguo Fu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhihui Dong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhihui Dong, M.D.</last_name>
    <phone>862164041990</phone>
    <phone_ext>2904</phone_ext>
    <email>dzh926@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhihui Dong</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihui Dong, M.D.</last_name>
      <phone>862164041990</phone>
      <phone_ext>2904</phone_ext>
      <email>dzh926@126.com</email>
    </contact>
    <investigator>
      <last_name>Weiguo Fu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhihui Dong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dong Z, Chen B, Fu W, Wang Y, Guo D, Wei Z, Xu X, Mendelsohn FO. Transplantation of purified CD34+ cells in the treatment of critical limb ischemia. J Vasc Surg. 2013 Aug;58(2):404-411.e3. doi: 10.1016/j.jvs.2013.01.037. Epub 2013 Apr 21.</citation>
    <PMID>23611711</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Thromboangiitis Obliterans</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
